Welcome to our dedicated page for Genenta Science Spa news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science Spa stock.
Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage immuno-oncology company developing Temferon™, a hematopoietic stem cell therapy platform aimed at solid tumor cancers. The GNTA news feed on Stock Titan aggregates company-issued updates, regulatory disclosures, and other coverage that shed light on how this platform is progressing through clinical development and corporate milestones.
News about Genenta frequently centers on its Temferon clinical programs, including the TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter and Phase 1/2a work in metastatic renal cell carcinoma and other genitourinary tumors. Company releases discuss survival trends, long-term follow-up observations, and exploratory immune findings related to tumor microenvironment reprogramming and T cell responses.
Investors following GNTA can also expect coverage of financing transactions such as registered direct offerings of American Depositary Shares, mandatory convertible bond financings with institutional partners, and the use of at-the-market facilities, as well as updates on cash and short-term investments in the context of funding clinical trials. Additional news items highlight strategic collaborations with organizations like Anemocyte and AGC Biologics for plasmid DNA and cell therapy manufacturing, along with participation in biotech conferences and sector events.
Corporate governance and leadership developments, including board appointments, changes in executive roles, amendments to by-laws, and disclosures about insider share ownership, are also reported through Genenta’s press releases and Form 6-K filings. For readers tracking GNTA stock, this news page provides a centralized view of the company’s clinical, financial, and strategic updates. Bookmark the GNTA news section to review new releases and historical announcements as Genenta advances its immuno-oncology platform.
Genenta Science (NASDAQ: GNTA) announced preliminary findings from its Phase 1/2a study of Temferon™ for glioblastoma multiforme (uMGMT-GBM). The results show Temferon's potential to modulate the tumor microenvironment, with a positive safety profile. Fifteen patients received the treatment, showing successful engraftment and no drug-limiting toxicities. Preliminary signals of biological activity were observed, including gene-marked cells in tumors of patients who underwent surgery. The findings will be presented at the ASGCT meeting on May 19, 2022.
Genenta Science (NASDAQ: GNTA) has announced the appointment of Mark A. Sirgo, PharmD, as the new Chair, succeeding Stephen Squinto, who is stepping down to pursue a new opportunity. Dr. Sirgo brings over 35 years of pharmaceutical experience, including a successful tenure as CEO of Biodelivery Sciences, where he raised over $600 million and increased the market cap from $10 million to nearly $1 billion. His appointment is subject to shareholder approval at the next AGM. The company is advancing its proprietary stem cell gene therapy Temferon™ in clinical trials for solid tumor cancers.
Genenta Science (NASDAQ: GNTA) announced a webinar titled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors," scheduled for April 28, 2022, at 8:00 AM EDT. Esteemed speakers include neuro-oncologist David Reardon from Harvard Medical School and gene therapy pioneer Luigi Naldini. The discussion will focus on Genenta's Temferon™, an innovative gene therapy aimed at treating glioblastoma and solid tumors. A Q&A session will follow. Registration is available via Genenta's news release.
Genenta Science (NASDAQ: GNTA) announced that it will present clinical data at the 2022 American Association for Cancer Research (AACR) meeting regarding its Temferon™ treatment for glioblastoma multiforme patients with unmethylated MGMT gene promoter (uMGMT-GBM). Data from 15 patients suggest successful engraftment of gene-modified cells and maintained levels for up to 18 months post-treatment.
Safety continues to be a focus, with manageable adverse events linked primarily to chemotherapy. The presentation is scheduled for April 8-13, 2022, in New Orleans.
Genenta Science (NASDAQ: GNTA) announced its participation in several upcoming investor conferences. The events include the 34th Annual ROTH Conference on March 13-15, Maxim Group LLC 2022 Virtual Growth Conference on March 28, and the HC Wainwright Gene Therapy and Gene Editing Conference on March 30. Management, including CEO Pierluigi Paracchi and CMO Carlo Russo, will engage in fireside chats and one-on-one meetings with investors. Genenta is focused on developing Temferon™, a novel gene therapy targeting solid tumors.
On December 17, 2021, Genenta Science (Nasdaq: GNTA) announced the completion of its upsized initial public offering, raising approximately $36 million by selling 2.4 million ADSs at $11.50 each, along with 720,114 ordinary shares to existing shareholders. The offering began trading on December 15, 2021. Roth Capital Partners and Maxim Group are involved in managing the offering. Additionally, the underwriters have a 30-day option to purchase an additional 360,000 ADSs, potentially increasing the total proceeds to around $40 million.
Genenta Science announced the pricing of its upsized initial public offering (IPO) of 2.4 million American Depositary Shares (ADSs), each priced at $11.50 per share. This offering is expected to generate approximately $36 million in gross proceeds, potentially rising to $40 million if underwriters exercise their purchase option. Trading under the ticker symbol GNTA on the Nasdaq begins on December 15, 2021, with the offering closing anticipated by December 17, 2021, pending customary conditions.